<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intravesical Bacillus Calmette-Guerin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intravesical Bacillus Calmette-Guerin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Intravesical Bacillus Calmette-Guerin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="102735" href="/d/html/102735.html" rel="external">see "Intravesical Bacillus Calmette-Guerin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F28182029"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Biohazard agent:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">BCG (intravesical) contains live, attenuated mycobacteria. Because of the potential risk for transmission, prepare, handle, and dispose of Bacillus Calmette-Guérin (BCG) as a biohazard material.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Disseminated infections:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">BCG infections have been reported in health care workers, primarily from exposures resulting from accidental needle sticks or skin lacerations during the preparation of BCG (intravesical) for administration. Nosocomial infections have been reported in patients receiving parenteral drugs that were prepared in areas where BCG (intravesical) was reconstituted. BCG is capable of dissemination when administered by the intravesical route, and serious infections, including fatal infections, have been reported in patients receiving intravesical BCG.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F28182035"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tice BCG</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871920"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Oncotice;</li>
<li>Verity-BCG</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F28182040"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Biological Response Modulator</li></ul></div>
<div class="block doa drugH1Div" id="F28182074"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3810c766-bd22-4b38-a74f-83d570ec742e">Bladder cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bladder cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">TICE BCG: Induction: <b>Intravesicular: </b>One dose (~50 mg or 1 vial) instilled into the bladder (retain for 2 hours) once weekly for 6 weeks beginning 7 to 14 days after biopsy (may repeat cycle 1 time if tumor remission not achieved), followed by maintenance therapy of ~50 mg (one vial) approximately once a month for at least 6 to 12 months.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Guideline recommendations: </i>According to the American Urological Association/Society of Urologic Oncology guideline on the diagnosis and treatment of nonmuscle invasive bladder cancer, and the Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for the treatment of urothelial cancer, BCG (intravesical) induction and 1 year of maintenance therapy should be considered for intermediate-risk disease; in high-risk disease, induction and 3 years of maintenance therapy should be administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27317986','lexi-content-ref-34266883']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27317986','lexi-content-ref-34266883'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990680"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987951"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dot drugH1Div" id="F46037460"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Bacterial urinary tract infection: Withhold BCG (intravesical) treatment until complete resolution of infection.</p>
<p style="text-indent:-2em;margin-left:2em;">Persistent fever or acute febrile illness consistent with BCG infection: Discontinue BCG (intravesical) treatment. Begin therapy with 2 or more antimycobacterial agents (do not use single agent therapy) while conducting a diagnostic evaluation.</p></div>
<div class="block doe drugH1Div" id="F28182075"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F28613961"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bladder mucosa irritation (bladder irritability: 60%), dysuria (52% to 60%), hematuria (26% to 38%), urinary frequency (40% to 50%), urinary urgency (6% to 50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Pain (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (24% to 33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (17% to 20%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac disorder (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (3%), skin rash (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), anorexia (≤2%), diarrhea (≤1%), nausea (≤7%), vomiting (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bladder pain (≤4%), bladder spasm (≤8%; including contracted bladder), cystitis (6%), epididymitis (≤1%), hemorrhagic cystitis (9%), nocturia (5%), orchitis (≤1%), prostatitis (≤1%), pyuria (≤1%), urethritis (≤1%), urinary incontinence (2% to 4%), urinary tract infection (2%), urinary tract obstruction (≤1%), urine sedimentation abnormality (debris: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (≤1%), disorder of hemostatic components of blood (≤1%), granuloma (hepatic: ≤1%), leukopenia (≤1%), thrombocytopenia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Abscess (genital; ≤2%), sepsis (BCG sepsis: ≤1%; including disseminated)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (9%), dizziness (≤2%), fatigue (≤7%), headache (≤2%), malaise (≤7%), neurologic abnormality (≤1%), rigors (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤3%), arthritis (≤3%), myalgia (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis (≤1%), respiratory system disorder (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Inflammation (genital; ≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: BCG infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Lethargy</p></div>
<div class="block coi drugH1Div" id="F28182052"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressed patients or persons with congenital or acquired immune deficiencies whether due to concurrent diseases (eg, HIV infection, leukemia, lymphoma), cancer therapy (cytotoxic drugs, radiation therapy), or immunosuppressive therapy (eg, corticosteroids); tuberculosis (TB) disease (active TB); concurrent febrile illness, urinary tract infection, or gross hematuria; recent (TICE BCG: &lt;7 to 14 days) biopsy, transurethral resection (TUR), or traumatic catheterization</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to BCG (intravesical) or any component of the formulation; invasive bladder cancer; concomitant use with antituberculosis drugs, including streptomycin, para-aminosalicylic acid, isoniazid, rifampicin, and ethambutol; pregnancy; breastfeeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F28182053"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• BCG reaction: A systemic granulomatous illness occurring following exposure to BCG is referred to as a systemic BCG reaction when any of the following are present without another detectable etiology: Febrile episodes with flu-like symptoms lasting &gt;72 hours; fever ≥39.5°C (103°F); pneumonitis; hepatitis; organ dysfunction outside of the GU tract with granulomatous inflammation; clinical signs of sepsis. It may be difficult to determine if reaction is due to infection process or inflammatory hypersensitivity. Fatalities have been reported with systemic BCG reactions. Local symptoms (prostatitis, epididymitis, orchitis) lasting &gt;2 to 3 days may also suggest active infection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bladder irritation: BCG (intravesical) may cause symptoms of bladder irritability which usually begin 4 to 6 hours after instillation and may last 24 to 72 hours; symptoms may increase in severity following each instillation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Disseminated infections: May cause disseminated (including fatal) infections following intravesical administration. Instillation to actively bleeding mucosa may promote systemic BCG infection or sepsis. To prevent serious infections, avoid trauma and/or introduction of contaminants into the urinary tract; postpone treatment for at least 1 to 2 weeks following TUR, biopsy, traumatic catheterization, or gross hematuria. Do not use in patients with concurrent infections. Use caution in patients with aneurysms and prosthetic devices; ectopic BCG infection may occur at these sites. Infection from BCG (intravesical) is not sensitive to pyrazinamide. Do not use prophylactic antimycobacterial therapy to prevent local adverse events during treatment (there is no data to support use and may alter efficacy). Determine PPD status prior to use (rule out tuberculosis [TB] disease [active TB] prior to treatment initiation). Prior to intravesical instillation, patients with a positive PPD test should be further assessed for signs and/or symptoms of TB infection (latent TB) or disease (active TB). BCG may persist in the urinary tract for several months after treatment; delayed manifestations of disseminated BCG infection may develop months to years after BCG therapy. Patients who receive immunosuppressive therapy after BCG therapy may be at higher risk for disseminated infection. Some male genitourinary tract infections (orchitis or epididymitis) have been refractory to multiple antituberculosis drug therapies and have required orchiectomy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Small bladder capacity: Intravesical instillation may be associated with increased risk of severe local reactions in the presence of small bladder capacity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary tract infection: If a bacterial urinary tract infection occurs during therapy, withhold instillation until complete resolution of infection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Packaging may contain natural latex rubber.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Biohazard agent: BCG (intravesical) contains live, attenuated mycobacteria. Use appropriate biohazard precautions for handling and disposal. BCG is a biohazard; properly prepare, handle, and dispose of all equipment in contact with BCG as a biohazard material. BCG infections have been reported in health care workers due to accidental exposure (needle stick, skin laceration); nosocomial infections have been reported in patients (including immunosuppressed patients) receiving parenteral medications prepared in areas where BCG was prepared. To avoid cross contamination, do not prepare parenteral medications in an area where BCG has been prepared.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: BCG (intravesical) is not a vaccine for the prevention of cancer.</p></div>
<div class="block foc drugH1Div" id="F28182085"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Intravesical [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tice BCG: 50 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F28182038"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F28182087"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Tice BCG Intravesical)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $188.48</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871921"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Intravesical: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oncotice: 50 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Verity-BCG: 40 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F28182078"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For intravesicular (bladder instillation) administration only; <b>do not administer IV, SUBQ, IM, or intradermally</b>.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Intravesicular:</b> Patients should not drink fluids for 4 hours prior to instillation. Empty or drain bladder. Instill BCG (intravesical) by gravity; remove catheter after instillation is complete. Retain BCG (intravesical) for as long as possible, up to 2 hours. Patient should lie prone for at least 15 minutes, then rotate positions (lie on right side, left side, abdomen, and back) every 15 minutes to maximize bladder surface exposure. Following bladder instillation, patients should be instructed to void in a seated position in order to avoid the splashing of urine; burning may occur with the first void following therapy. Prior to flushing, disinfect the urine for 15 minutes with an equal amount of household bleach (this should be done for the first 6 hours after each instillation). After administration, patients should drink plenty of water in order to flush the bladder.</p></div>
<div class="block hazard drugH1Div" id="F49130889"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F28182044"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bladder cancer:</b> Treatment and prophylaxis of carcinoma in situ of the urinary bladder; prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: BCG (intravesical) is not recommended for stage TaG1 (low-grade) papillary tumors unless judged to be at high risk for recurrence. BCG (intravesical) is not recommended for papillary tumors of stages higher than T1. BCG (intravesical) is not recommended for immunization against tuberculosis.</p></div>
<div class="block mst drugH1Div" id="F28182031"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">BCG (intravesical) may be confused with BCG vaccine (immunization)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F28182062"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F28182059"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antibiotics: May diminish the therapeutic effect of BCG (Intravesical).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of BCG Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hexaminolevulinate: BCG (Intravesical) may diminish the diagnostic effect of Hexaminolevulinate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of BCG Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Methotrexate may diminish the therapeutic effect of BCG Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Myelosuppressive Agents: May diminish the therapeutic effect of BCG (Intravesical).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Teplizumab may diminish the therapeutic effect of BCG Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ustekinumab: May enhance the adverse/toxic effect of BCG Products. Specifically, the risk of infection may be increased. Ustekinumab may diminish the therapeutic effect of BCG Products.<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49095575"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who may become pregnant should be advised to avoid pregnancy while on BCG (intravesical) therapy.</p></div>
<div class="block pri drugH1Div" id="F28182048"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted. BCG (intravesical) is not recommended for use during pregnancy.</p></div>
<div class="block brc drugH1Div" id="F28182051"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if BCG (intravesical) is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, a decision should be made to discontinue breastfeeding or avoid use of BCG (intravesical), taking into account the importance of BCG (intravesical) to the patient.</p></div>
<div class="block mop drugH1Div" id="F28182080"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">PPD test prior to initiation</p>
<p style="text-indent:-2em;margin-left:2em;">Intravesical treatment: Monitor for signs/symptoms of toxicity/infection following every treatment. Signs that antituberculous therapy may be needed: Flu-like symptoms ≥72 hours, fever ≥101.3°F, systemic symptoms which worsen with each treatment, persistently abnormal liver function tests, prostatitis, epididymitis or orchitis of &gt;2 to 3 day duration</p></div>
<div class="block pha drugH1Div" id="F28182070"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">BCG (intravesical) is an attenuated strain of bacillus Calmette-Guérin (<i>Mycobacterium bovis</i>) used as a biological response modifier. BCG, when used intravesicularly for treatment of bladder carcinoma <i>in situ</i>, is thought to cause a local, chronic inflammatory response involving macrophage and leukocyte infiltration of the bladder. BCG (intravesical) is active immunotherapy which stimulates the host's immune mechanism to reject the tumor.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F28182089"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Oncotice</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Oncotice</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Tice bcg</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27317986">
<a name="27317986"></a>Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. <i>J Urol.</i> 2016;196(4):1021-1029. doi:10.1016/j.juro.2016.06.049<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/intravesical-bacillus-calmette-guerin-drug-information/abstract-text/27317986/pubmed" id="27317986" target="_blank">27317986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34266883">
<a name="34266883"></a>Galsky MD, Balar AV, Black PC, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. <i>J Immunother Cancer. </i>2021;9(7): e002552. doi:10.1136/jitc-2021-002552<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/intravesical-bacillus-calmette-guerin-drug-information/abstract-text/34266883/pubmed" id="34266883" target="_blank">34266883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oncotice.1">
<a name="Oncotice.1"></a>Oncotice (BCG) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TICE.1">
<a name="TICE.1"></a>TICE BCG [prescribing information]. Rahway, NJ: Merck &amp; Co Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li></ol></div><div id="topicVersionRevision">Topic 102734 Version 100.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
